Life Sciences Research for Lifelong Health

Type

Events

Tagged

camntf
networking

Cambridge New Therapeutics Forum - November event

The next Cambridge New Therapeutics Forum (CamNTF) will take place this month, hosted by AstraZeneca.  CamNTF, which launched in 2015, hosts early-evening meetings open to all scientists interested in research into new therapeutics. These rotate around different organisations located in the Cambridge biotech cluster. Each two-hour session will begin with short scientific presentations and will be followed by networking and snacks.

Cam NTF is a scientific forum open to all scientists interested in research and development of new therapeutics in Cambridge and the local area, including scientists at the University, Addenbrooke’s Hospital, pharmaceutical companies, biotechs, CROs, and not-for-profit organisations. The purpose of CamNTF is to promote interactions between scientists at these organisations in order to improve opportunities for biotechnology research and development.

The next of these sessions will be held on 16 November.
All are welcome to attend for free but registration is required.

The purpose of Cambridge New Therapeutics Forum (CamNTF) is to promote interactions between scientists at these organisations in order to improve opportunities for biotechnology research and development. November's CamNTF will feature talks from Mark Fidock, VP and Head, Personalised Healthcare and Biomarker Laboratories, AstraZeneca, Prof Ludovic Vallier, University of Cambridge/ Wellcome Trust Sanger Institute, David Hughes, Chief Technical Officer, CN Bio Innovations and Rhiannon David, Senior Scientist, Drug Safety and Metabolism, AstraZeneca
 
Theme: Advances in Patient Relevant In Vitro Models

Programme:
17:30 – Arrival, Registration, Tea & Coffee
18:00 – Introduction, Dr Mark Fidock, VP and Head, Personalised Healthcare and Biomarker Laboratories, AstraZeneca
18:10 – Professor Ludovic Vallier, University of Cambridge & Wellcome Trust Sanger Institute: Human Pluripotent Stem Cells to Model and to Study Liver Disease
18:40 – Dr David Hughes, Chief Technical Officer, CN Bio Innovations: Microphysiological Systems for Drug Discovery
18:55 – Dr Rhiannon David, Senior Scientist, Drug Safety and Metabolism, AstraZeneca: Microphysiological Systems: Their Development and Application in the Pharmaceutical Industry
19:10 – Networking and Refreshments
20:00 - Meeting Close

For more information, including a full programme and to register for free, click here
 

Posted

1 November, 2017